Clinilabs
, an early phase and specialty CRO that provides clinical drug development services to the pharmaceutical industry, today announced that they have opened a second Phase I unit in Southern New Jersey. The 50-bed capacity, 15,000 square foot Specialty Pharma Phase I Unit features semi private rooms, a large PK sampling facility, a bioanalytic laboratory, pharmacy, and exam rooms.
Since 2001, Clinilabs has successfully completed clinical trials involving healthy, adult human volunteers and specialty patient populations. The staff has accrued experience in over 800 clinical studies, offering clients the service capacity of a big CRO—delivered by an organization that is right-sized and priced for early phase projects. The opening of the New Jersey Specialty Pharma Phase I Unit expands services currently offered at the company’s 50 bed, state-of-the-art, Phase I unit in Manhattan, raising total bed capacity to 100.
“I am pleased to announce the opening of our new unit in Eatontown, New Jersey”, states Gary Zammit, PhD. “This unit allows us to expand our Phase I capacity in two locations, providing first-in-human through end-of-phase II CRO services to our clients. We are now able to enroll larger samples of normal healthy volunteers and patient populations at our two units and at investigator sites worldwide.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.